Zabadinostat
As of the edition of 20 October 2026, Zabadinostat is a small molecule: stopped in 2026; acts on HDAC9.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2026
- Kind
- Small molecule
- Registered trials
- 4, 1 stopped early
- Disease areas
- Cancer; Digestive system; Blood and lymph; Hormones; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| HDAC9 | Histone deacetylase 9 | Q9UKV0 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 1 | 0 | 1 |
| Phase 2 | 2 | 0 | 1 | 0 |
| All trials | 4 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Celleron Therapeutics | Lead sponsor of trials | 2018 to now |
| Immunitybio | Lead sponsor of trials | 2026 to now |